| 000 | 01689 a2200469 4500 | ||
|---|---|---|---|
| 005 | 20250517151956.0 | ||
| 264 | 0 | _c20180409 | |
| 008 | 201804s 0 0 eng d | ||
| 022 | _a1880-3873 | ||
| 024 | 7 |
_a10.5551/jat.39446 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aShinnakasu, Atsushi | |
| 245 | 0 | 0 |
_aThe Combination Therapy of Fenofibrate and Ezetimibe Improved Lipid Profile and Vascular Function Compared with Statins in Patients with Type 2 Diabetes. _h[electronic resource] |
| 260 |
_bJournal of atherosclerosis and thrombosis _cJul 2017 |
||
| 300 |
_a735-748 p. _bdigital |
||
| 500 | _aPublication Type: Comparative Study; Journal Article | ||
| 650 | 0 | 4 |
_aAnticholesteremic Agents _xtherapeutic use |
| 650 | 0 | 4 |
_aBiomarkers _xblood |
| 650 | 0 | 4 |
_aDiabetes Mellitus, Type 2 _xblood |
| 650 | 0 | 4 | _aDrug Therapy, Combination |
| 650 | 0 | 4 |
_aEzetimibe _xtherapeutic use |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aFenofibrate _xtherapeutic use |
| 650 | 0 | 4 | _aFollow-Up Studies |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aHydroxymethylglutaryl-CoA Reductase Inhibitors _xtherapeutic use |
| 650 | 0 | 4 |
_aHypolipidemic Agents _xtherapeutic use |
| 650 | 0 | 4 |
_aLipids _xblood |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aPrognosis |
| 700 | 1 | _aYamamoto, Kiyoaki | |
| 700 | 1 | _aKurano, Mihoko | |
| 700 | 1 | _aArimura, Hiroshi | |
| 700 | 1 | _aArimura, Aiko | |
| 700 | 1 | _aKikuti, Akira | |
| 700 | 1 | _aHashiguchi, Hiroshi | |
| 700 | 1 | _aDeguchi, Takahisa | |
| 700 | 1 | _aNishio, Yoshihiko | |
| 773 | 0 |
_tJournal of atherosclerosis and thrombosis _gvol. 24 _gno. 7 _gp. 735-748 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.5551/jat.39446 _zAvailable from publisher's website |
| 999 |
_c27120964 _d27120964 |
||